Skip to the main content

Review article

https://doi.org/10.20471/acc.2018.57.01.18

Sexual Activity in Patients with Cardiac Diseases

Marko Mornar Jelavić ; Institute for Cardiovascular Prevention and Rehabilitation, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia; 3School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Goran Krstačić ; Institute for Cardiovascular Prevention and Rehabilitation, Zagreb, Croatia; 3School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Aleksandra Perenčević ; Department of Internal Medicine and Dialysis, Zagreb-East Health Center, Zagreb, Croatia
Hrvoje Pintarić ; School of Dental Medicine, University of Zagreb, Zagreb, Croatia; Cardiac Catheterization Laboratory, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia


Full text: english pdf 629 Kb

page 141-148

downloads: 1.271

cite


Abstract

In this article, we outline the latest guidelines published by the American Heart Association on sexual activity in patients with coronary artery disease, heart failure, structural heart diseases, arrhythmias, implanted pacemakers or cardioverter defibrillators, as well as on treatment options of sexual dysfunction. Sexual activities are similar to mild/moderate physical activity during a short period. Most patients are recommended to involve in sexual activity after prior comprehensive evaluation of physical condition. Those with stable cardiac symptoms and good functional capacity are at a low risk of adverse cardiovascular events, and others require treatment or stabilization before involving in sexual activity. Stress testing is useful in evaluating safety of sexual activity in patients with questionable or undetermined risk. Treatment of sexual dysfunction includes counseling of patients and their sexual partners, and drug treatment with phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil) which have been demonstrated to be safe and effective, in men, and with serotonin reuptake inhibitors (flibanserin) and local vaginal estrogen administration in women. In conclusion, in routine clinical practice, patients should be approached individually and multidisciplinarily in order to detect and eliminate the factors that interfere with normal sexual activities and disturb the quality of life.

Keywords

Cardiovascular diseases; Sexual dysfunction, physiological – drug therapy; Sexual behavior; Quality of life

Hrčak ID:

202208

URI

https://hrcak.srce.hr/202208

Publication date:

1.3.2018.

Article data in other languages: croatian

Visits: 4.313 *